PPHM : Analysis & Opinions

  1. Cytokinetics' Update on Study - Analyst Blog

    July 9, 2013
    A programming error was reported by the company's data management vendor.
  2. Data on Peregrine's Bavituximab - Analyst Blog

    February 14, 2013
    Peregrine Pharmaceuticals (PPHM) recently announced phase II data on its oncology candidate, bavituximab. The open-label, ...
  3. Medivation's Xtandi Impresses - Analyst Blog

    February 7, 2013
    Medivation, Inc. (MDVN) recently announced that its partner Astellas Pharma Inc. (ALPMY) reported Xtandi (enzalutamide) sales ...
  4. Geron's Update on Stem Cell Assets - Analyst Blog

    January 10, 2013
    Geron Corporation (GERN) announced that it has signed an Asset Contribution Agreement with BioTime, Inc. (BTX) and BioTime's ...
Investing News
  1. 3 Dumb Ways to Borrow Money

    Money — everyone needs it, but not everyone has it. Many people who find themselves in a ...
  2. Infographic - The Lifecycle of a Bond

    Basic information on how Bonds work.
  3. What $200,000 Will Buy In The Atlanta Real Estate Market

    Atlanta housing prices are up from last year, but they're still lower than the national median. ...
  4. Bubble Bursting? Only For Biotech & Internet Stocks

    The recent sluggish performance of U.S. stocks is leading some market watchers to question ...
  5. What $300,000 Will Buy In The Riverside/San Bernardino Real Estate Market

    The median list price for the San Bernardino/Riverside, Calif. market is $292,800, up 24.6% ...
  6. What Is Worse Than Being At Risk?

    You may have heard the old adage: “What is worse than being lost? Not knowing you are lost.” ...
Trading Center